New drug combo shows promise for rare childhood muscle disease

NCT ID NCT05524311

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug baricitinib, given with steroids, in 16 children aged 3-18 with newly diagnosed juvenile dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if baricitinib works better than the standard treatment (methotrexate plus steroids) at improving muscle strength and daily activities over 24 weeks. The approach aims to control the disease with a good safety profile, but ongoing management is still needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatomyositis juvenile dermatomyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

JUVENILE DERMATOMYOSITIS

Contacts and locations

Locations

Hopital Necker - Enfants malades : unité d'immuno-hématologie et rhumatologie

Paris, France
Hôpital Brabois

Nancy, France
Hôpital Femme Mère Enfant

Bron, France
Hôpital Jeanne de Flandre

Lille, France
Hôpital La Timone

Marseille, France
Hôpital Necker - Enfants malades : service de dermatologie

Paris, France
Hôpital Pellegrin

Bordeaux, France
Hôpital Purpan

Toulouse, France
Hôpital Robert Debré

Paris, France
Hôpital Trousseau

Paris, France
Hôpital Villeneuce

Montpellier, France
Hôpital de Hautepierre

Strasbourg, France
Hôpital du Kremlin-Bicêtre

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.